0001663577-26-000087
SEC filingSkinvisible faces a critical year with deepening losses and severe liquidity constraints, as its survival hinges on successful licensing deals and external financing to sustain operations.
Skinvisible's fiscal year 2025 was marked by continued financial strain, with revenue remaining flat at $20.0K, unchanged from the prior year. This stagnation reflects the company's ongoing challenge in monetizing its patented Invisicare technology, despite having completed development of unique products and secured key US and international patents that enhance product demand. The company operates with a 100% gross margin, as shipping and handling costs are not a significant portion of cost of revenue, but this high margin is overshadowed by substantial operating losses.
Operating losses showed some improvement, with operating income at -$496.3K compared to -$589.6K in the prior year, representing a 15.8% year-over-year improvement. However, net loss deepened significantly to -$1.1M, an 88.1% deterioration from the prior year's -$565.7K loss. This widening net loss was primarily driven by interest expense on convertible debt and related-party notes, as the company relies on financing from related parties to support operations.
The company's liquidity position remains precarious, with operating activities using $38,410 in cash for the year ended December 31, 2025, compared to $69,834 used in the prior year. While this represents an improvement in cash burn, management has explicitly stated there is substantial doubt about the company's ability to continue as a going concern. The financial statements have been prepared on a going concern basis, which assumes the realization of assets and satisfaction of liabilities in the normal course of business, but this assumption is challenged by current circumstances.
Management acknowledges that there can be no assurance the company will be successful in raising additional capital. The company's positive financing cash flow in prior periods resulted from proceeds from related party notes, highlighting its dependence on insider financing. With only two employees and minimal infrastructure, the company faces significant operational risks that compound its financial challenges.
Skinvisible's business model relies entirely on out-licensing its patented technology, as it has no internal manufacturing or commercial sales capabilities. This creates dependency on third-party licensees' success and timeliness. The company anticipates generating revenues through licensing of its core products and expects operating expenses to increase as licensing revenue grows. If licensing revenue proves insufficient, management may seek to raise additional operating capital through offerings of common stock or debt to implement the business plan.
The company operates as one reportable and operating segment, focusing exclusively on technology licensing. Management has identified a material weakness in internal control over financial reporting relating to an ineffective risk assessment process and insufficient written policies. Remediation of this control deficiency is dependent on securing additional financing to hire qualified personnel, creating a circular challenge where improved controls require funding that may not be available.
Looking forward, Skinvisible's survival depends on successful execution of its licensing strategy and ability to secure external financing. The company faces intense competition from firms with greater resources and must navigate regulatory complexities across pharmaceutical and skincare markets in multiple jurisdictions. These factors collectively represent the fundamental challenge of transitioning from a development-stage company to a sustainable, revenue-generating enterprise.